Among these, NUTM2B followed by NUTM2A represents the most frequently involved members in oncogene fusions, while NUTM2G has been only recently encountered in subsets of NUT sarcomas defined by MYC‐associated factor X dimerization (MAD) protein family (MXI1, MXD4, and MGA) gene fusions, mostly fused to NUTM1, but rarely to NUTM2A and NUTM2G (MXD4::NUTM2G and MXI1::NUTM2A in one case each) [16]. The gene discussed is NUTM2A; the disease is sarcoma.